Lombardia GENS: a collaborative registry for monogenic diseases associated with stroke.

To share our experience of sinonasal cancer management as a tertiary center.This is a retrospective study from a single tertiary center. The staging was performed according to the AJCC, 8th edition.A total of twenty-six patients were included in the study. The majority of the patients were male (76.9%), with the maxillary sinus as the primary tumor being predominant (80.8%), as was squamous cell histology (65.5%). T4 tumors at diagnosis accounted for 61.5% of the patients. The local recurrence rate was 23.1%. Induction chemotherapy was the initial treatment choice for 11.5% (n = 3) of the patients. Primary surgery was selected for 7.7% of the patients, and chemoradiotherapy was the treatment choice for 53.8%. The median follow-up duration was 56 months (95%CI: 29.8-82.1). The median overall survival (OS) was not reached, with 61.5% of patients remaining alive. The median disease-free survival (DFS) was not reached. Additionally, 61.5% of patients did not experience local recurrence or metastasis. Local recurrence was identified as an adverse prognostic factor for OS (NR vs 30 months, 95%CI 0.543-59.457, p = 0.037). Intracranial extension was identified as an adverse prognostic factor for DFS (NR vs. 7 months, 95%CI 0-14.321, p = 0.019).SNCs are rare and heterogeneous cancers that require a multidisciplinary management approach. Due to nonspecific symptoms, most patients are diagnosed at advanced stages. More prospective data are needed to optimize patient care.